SCHEMBL3235232

SCHEMBL3235232

Cc1ccc(S(=O)(=O)O[C@H]2CCN(S(=O)(=O)c3ccc(C)cc3)C2)cc1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.59
CYP1A2 P05177 1/20 0.57
PKM P14618 3/20 0.51
ALDH1A1 P00352 6/20 0.51
KDM4E B2RXH2 1/20 0.51
POLB P06746 1/20 0.50
HTT P42858 1/20 0.50
KMT2A Q03164 4/20 0.49
MEN1 O00255 2/20 0.49
MAPT P10636 2/20 0.49
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
LMNA P02545 2/20 0.47
EBP Q15125 1/20 0.47
DHCR7 Q9UBM7 1/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3235228 1.00 CYP2D6 (0.59) CYP2D6CYP1A2PKMALDH1A1KDM4E
SCHEMBL6863028 1.00 CYP2D6 (0.59) CYP2D6CYP1A2PKMALDH1A1KDM4E
SCHEMBL8425188 0.92 ALDH1A1 (0.56) CYP2D6CYP1A2PKMALDH1A1KDM4E
SCHEMBL6881853 0.92 ALDH1A1 (0.56) CYP2D6CYP1A2PKMALDH1A1KDM4E
SCHEMBL8879797 0.91 CYP2D6 (0.66) CYP2D6CYP1A2PKMALDH1A1KDM4E
SCHEMBL841102 0.89 DHCR7 (0.53) CYP2D6CYP1A2KMT2AMEN1MAPT
SCHEMBL20594955 0.89 CYP2D6 (0.59) CYP2D6CYP1A2PKMALDH1A1KDM4E
SCHEMBL7466566 0.86 ALDH1A1 (0.49) CYP2D6CYP1A2PKMALDH1A1KDM4E
SCHEMBL24479773 0.85 HSD11B1 (0.54) PKMALDH1A1KDM4EPOLBHTT
SCHEMBL420300 0.82 CYP2D6 (0.74) CYP2D6CYP1A2PKMPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2109601-A2 PREPARATION OF DARIFENACIN AND ITS SALTS Dr. Reddy's Laboratories Ltd. (IN) 2009-10-21 EP claimed
WO-2009125430-A2 IMPROVED PROCESS FOR PRODUCING DARIFENACIN MATRIX LABORATOIRES LIMITED (IN) 2009-10-15 WO claimed
WO-2008100651-A2 PREPARATION OF DARIFENACIN AND ITS SALTS DR. REDDY'S LABORATORIES LTD. (IN) 2008-08-21 WO claimed
WO-2009125430-A3 IMPROVED PROCESS FOR PRODUCING DARIFENACIN MATRIX LABORATOIRES LIMITED (IN) 2010-04-22 WO disclosed
WO-2009125430-A8 IMPROVED PROCESS FOR PRODUCING DARIFENACIN MATRIX LABORATOIRES LIMITED (IN) 2010-01-21 WO disclosed
WO-2009153649-A1 PROCESS FOR PREPARING 3-SUBSTITUTED PYRROLIDINE COMPOUNDS MEDICHEM, S.A. (ES) 2009-12-23 WO disclosed
EP-2109601-A2 PREPARATION OF DARIFENACIN AND ITS SALTS Dr. Reddy's Laboratories Ltd. (IN) 2009-10-21 EP disclosed
WO-2009125430-A2 IMPROVED PROCESS FOR PRODUCING DARIFENACIN MATRIX LABORATOIRES LIMITED (IN) 2009-10-15 WO disclosed
WO-2009125430-A2 IMPROVED PROCESS FOR PRODUCING DARIFENACIN MATRIX LABORATOIRES LIMITED (IN) 2009-10-15 WO disclosed
WO-2009125430-A2 IMPROVED PROCESS FOR PRODUCING DARIFENACIN MATRIX LABORATOIRES LIMITED (IN) 2009-10-15 WO disclosed
WO-2009125426-A2 NOVEL PROCESS FOR THE PREPARATION OF (3SM-[2-(2 J-DIHYDRO-5- BENZOFURANYLϊETHYL]-α.α -DIPHENYL-3-PYRROLIDINEACETAMIDE HYDROBROMIDE NEULAND LABORATORIES LTD (IN) 2009-10-15 WO disclosed
US-5281601-A Imide substituted indoline derivatives PFIZER INC. (US) 1994-01-25 US disclosed
EP-0388054-B1 Pyrrolidine derivatives PFIZER LTD (GB) 1993-11-03 EP disclosed
US-5233053-A Pyrrolidine derivatives PFIZER INC. (US) 1993-08-03 US disclosed
EP-0505376-A1 MUSCARINIC RECEPTOR ANTAGONISTS. PFIZER LTD (GB) 1992-09-30 EP disclosed
EP-0505377-A1 MUSCARINIC RECEPTOR ANTAGONISTS. PFIZER LTD (GB) 1992-09-30 EP disclosed
US-5096890-A PYRROLIDINE DERIVATIVES PFIZER INC. (US) 1992-03-17 US disclosed
WO-1991009015-A1 MUSCARINIC RECEPTOR ANTAGONISTS PFIZER LIMITED (GB) 1991-06-27 WO disclosed
WO-1991009013-A1 MUSCARINIC RECEPTOR ANTAGONISTS PFIZER LIMITED (GB) 1991-06-27 WO disclosed
EP-0388054-A1 Pyrrolidine derivatives Pfizer Limited (GB) 1990-09-19 EP disclosed